Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is pioneering a new approach to cardiovascular disease detection and management by harnessing artificial intelligence (AI), genetics, and epigenetics. The company's platform integrates genetic and epigenetic biomarkers with AI-driven analytics to provide personalized cardiovascular insights from blood-based testing, aiming to improve prevention, detection, and treatment of cardiovascular disease.
Cardio Diagnostics currently offers two clinical solutions: Epi+Gen CHD and PrecisionCHD. Epi+Gen CHD is a blood test that combines genetic and epigenetic markers to assess the risk of coronary heart disease, while PrecisionCHD provides a more comprehensive evaluation to guide personalized intervention strategies. The company also offers population health and biopharma solutions: HeartRisk, designed for population-level risk management, and CardioInnovate360, which supports therapeutic development.
The need for such tools is critical. Cardiovascular disease remains the leading cause of death globally, and traditional risk assessment methods often fail to identify individuals at high risk until after a cardiac event. Cardio Diagnostics' approach aims to shift the paradigm from reactive treatment to proactive prevention. By identifying risk earlier, healthcare providers can implement personalized prevention plans, potentially reducing the incidence of heart attacks and strokes.
According to the company, its proprietary AI-driven Integrated Genetic-Epigenetic Engine (Core Technology) is central to its offerings. This technology analyzes a patient's genetic and epigenetic data to provide a precise risk profile, enabling more targeted interventions. The company believes this approach can also help in the development of new therapeutics by identifying patient populations most likely to respond to specific treatments.
The implications for patients and the healthcare system are significant. Early detection could lead to better outcomes and lower healthcare costs by reducing the need for expensive emergency interventions. For the broader industry, Cardio Diagnostics' solutions represent a shift toward precision medicine in cardiovascular care, a field that has traditionally relied on population-based risk factors rather than individual biological markers.
The company's newsroom and additional updates are available at https://ibn.fm/CDIO. For more details on the featured article, visit https://ibn.fm/Nfps9.
